Adjuvant technology, a Belgian expertise
In our work in Belgium, we are pioneers in the development of adjuvants, components that can stimulate the immune system to fight infectious diseases. These adjuvants have been crucial in the development of vaccines against pandemic influenza, shingles, malaria, but also in the ongoing development of new vaccines against bacterial and viral diseases including COVID-19.
Accelerating pipeline innovation
We are working to revolutionise healthcare, using cutting-edge data and platform technologies. We apply our expertise in data and analytical tools as well as platform technologies to advance and accelerate the discovery, development and delivery of innovative medicines and vaccines for people worldwide.
Data tech helps us to gain a deep understanding of the patient, human biology, and disease mechanisms. Through the use of genetic data, AI and machine learning, we can unravel the mysteries of disease to design our vaccines and medicines to optimise clinical effect. We do this by matching genetic targets with the most effective tech platform such as oligonucleotides, mRNA, small molecules and monoclonal antibodies. This means we can tackle more challenging diseases that were once considered too difficult to target.
Driving performance to reach patients better and faster
Our depth and breadth of data and integrated use of tech across every part of our business is accelerating our performance and improving how we help patients.
From AI and robotics to data tech, we're transforming our supply chain, empowering our people with data tech and supporting the entire patient journey.
Approximately 70% of our targets in research are genetically validated
The success of our research and development activities lies not only in discovering new treatments, but also in improving the processes for identifying them. The key to this success lies in the combination of human genetics, genomics and advanced technologies. To fulfil our purpose to get ahead of disease together, we prioritise genetically validated targets to increase our probability of successfully delivering an approved vaccine or medicine, thereby having the greatest impact to improve patient lives. Published scientific research shows that genetically validated targets are at least twice as likely to become medicines.
Cultivating a tech-enabled culture
We empower our people to find solutions by cultivating a tech-enabled culture. We also automate and scale processes and tasks where tech can provide faster and more precise solutions. This frees up our talented workforce to focus on what they do best - solving complex problems using creativity, human judgement and deep expertise.
Partnerships in Belgium
In addition to these technologies, GSK is also investing in partnerships to develop them further. One of the latest partnerships is with imec, a leading nanotechnology research centre based in Flanders. The partnership between GSK and imec follows a year of exploratory research with promising preliminary results. In R&D, GSK and imec will explore the role of nanotechnology in accelerating the development and production of new vaccines through innovative solutions. In biomanufacturing, nanotechnology will be used to automate and improve the control of production processes.
